{"entity":{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","aka":[],"tldr":"Led CheckMate 649, which made immunotherapy plus chemotherapy the first-line standard for gastric cancer, and the pembrolizumab-trastuzumab combination in HER2-positive disease.","summary":"Yelena Y. Janjigian is Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. She is a gastrointestinal oncologist known for leading CheckMate 649, which made nivolumab plus chemotherapy the first-line standard for gastric cancer, and KEYNOTE-811, which established pembrolizumab with trastuzumab in HER2-positive disease. Her selected papers report first-line nivolumab plus chemotherapy in advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, and the KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Her research programme focuses on HER2 and immune biomarkers in gastro-oesophageal cancer.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/yelena-janjigian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janjigian%20YY%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":["pd1","her2"],"drugs":["nivolumab","pembrolizumab","trastuzumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-649"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Gastrointestinal Oncology Service","institutionId":"mskcc","specialisms":["Gastric and oesophageal cancer","HER2-positive GI cancer","Immunotherapy"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/yelena-janjigian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janjigian%20YY%5BAuthor%5D"}],"papers":[{"title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)00797-2","doi":"10.1016/S0140-6736(21)00797-2"},{"title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","journal":"Nature","year":2021,"url":"https://doi.org/10.1038/s41586-021-04161-3","doi":"10.1038/s41586-021-04161-3"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"},{"title":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)02033-0","doi":"10.1016/S0140-6736(23)02033-0"}]},"route":"/people/yelena-janjigian/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/"},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/"}],"paper":[{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/"}]}}